-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297

Benzinga·08/11/2026 15:13:02
Listen to the news
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $304 to $297.